Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 3,700 shares of the stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $30.08, for a total value of $111,296.00. Following the completion of the sale, the insider owned 56,450 shares in the company, valued at approximately $1,698,016. The trade was a 6.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Anne Lesage also recently made the following trade(s):
- On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $580,992.00.
- On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $656,642.00.
- On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.
- On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $225,375.00.
- On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
Pharvaris Price Performance
Pharvaris stock opened at $29.44 on Friday. Pharvaris N.V. has a 1-year low of $14.59 and a 1-year high of $31.14. The stock has a market cap of $1.93 billion, a PE ratio of -8.74 and a beta of -2.34. The stock's fifty day moving average is $27.62 and its two-hundred day moving average is $26.03.
Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). On average, research analysts expect that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.
Pharvaris News Roundup
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
- Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
- Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
- Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
- Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing
Hedge Funds Weigh In On Pharvaris
A number of large investors have recently made changes to their positions in the stock. Wellington Management Group LLP purchased a new stake in shares of Pharvaris during the 3rd quarter worth approximately $43,282,000. Paradigm Biocapital Advisors LP raised its position in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock worth $45,796,000 after purchasing an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Pharvaris during the 3rd quarter worth approximately $15,613,000. Commodore Capital LP raised its position in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company's stock worth $60,341,000 after purchasing an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. raised its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock worth $200,380,000 after purchasing an additional 500,000 shares during the last quarter.
Analysts Set New Price Targets
PHVS has been the topic of several research reports. Royal Bank Of Canada dropped their price objective on Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a report on Monday, April 6th. Wolfe Research assumed coverage on Pharvaris in a research report on Thursday, April 9th. They set an "outperform" rating and a $42.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research note on Tuesday, April 21st. HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Citigroup restated a "buy" rating on shares of Pharvaris in a research report on Wednesday, April 15th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $42.73.
Check Out Our Latest Research Report on PHVS
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
